DRG Epidemiology's coverage of idiopathic pulmonary fibrosis comprises epidemiological estimates of key patient populations globally, including the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of idiopathic pulmonary fibrosis for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology's idiopathic pulmonary fibrosis forecast will answer the following questions:

  • Of all people with idiopathic pulmonary fibrosis, how many in each country have been formally diagnosed?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of idiopathic pulmonary fibrosis over the forecast period?
  • How many people with diagnosed idiopathic pulmonary fibrosis also have gastroesophageal reflux disease, pulmonary hypertension, emphysema and obstructive sleep apnea?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following idiopathic pulmonary fibrosis patient populations:

  • Diagnosed prevalent cases
  • Diagnosed prevalent cases with comorbid gastroesophageal reflux disease
  • Diagnosed prevalent cases with comorbid emphysema
  • Diagnosed prevalent cases with comorbid obstructive sleep apnea

Table of contents

  • Idiopathic Pulmonary Fibrosis - Epidemiology - Emerging Markets

Author(s): Abey John, MPH

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.


Related Reports

Idiopathic Pulmonary Fibrosis - Epidemiology - Epidemiology Dashboard

DRG Epidemiology's coverage of idiopathic pulmonary fibrosis comprises epidemiological estimates of key patient populations globally, including the major mature pharmaceutical markets (the Unit...

View Details

Idiopathic Pulmonary Fibrosis - Epidemiology - Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key idiopathic pulmonary fib...

View Details

Idiopathic Pulmonary Fibrosis - Landscape & Forecast - Disease Landscape & Forecast

Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases and is characterized by an ir...

View Details

Idiopathic Pulmonary Fibrosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irr...

View Details